This site uses cookies. By using this site you agree to receiving cookies. View Policy.
TC BioPharm is a world-leading immunotherapy company that has seen positive results in its latest clinical cancer trial. They are now looking to advance those trials as well as extend their IP protected technology to a COVID-19 therapy, having recently received regulatory approval for a Phase I trial.
Allogeneic CAR-T Specialists TC BioPharm Appoint Prof John Anderson as Scientific and Medical Director PRNewsWire |
29/03/2019 |
Allogeneic CAR-T Specialists TC BioPharm Appoint Prof John Anderson as Scientific and Medical Director Markets Insider |
29/03/2019 |
TC BioPharm appoints renowned professor as scientific and medical director insider.co.uk |
29/03/2019 |
TC BioPharm announces Maxim Park 10k sq ft expansion Scotsman |
18/03/2019 |
Made in Scotland winner TC Biopharm goes from strength to strength with Ireland tie-up insider.co.uk |
11/03/2019 |
SC453579
01/07/2013
Active
Research and experimental development on biotechnology
7
Date | Amount | No. of Investors | |
---|---|---|---|
02/12/2020 | £1,751,820 | 676 | View |
Name | Role | Appointed | Nationality |
---|---|---|---|
RINTOUL, Toby | Secretary | 18/08/2018 | |
CLARK, Alan George | Director | 16/07/2016 | British |
LEEK, Michael David, Dr | Director | 13/07/2013 | British |
MINOURA, Kimihito | Director | 19/10/2019 | Japanese |
PORTER, Lorraine Christie | Director | 15/07/2015 | British |
SCOTT, Angela Rita Rafaella | Director | 18/12/2018 | British |
THORP, Martin | Director | 16/03/2016 | British |